NCT05626322 is a Phase 1, PHASE2 clinical trial of Maplirpacept in Diffuse Large B-Cell Lymphoma, sponsored by Pfizer.

Who is sponsoring NCT05626322?

NCT05626322 is sponsored by Pfizer.

What drugs are being tested in NCT05626322?

Interventions in NCT05626322: Maplirpacept, Tafasitamab, Lenalidomide.

What condition does NCT05626322 study?

NCT05626322 studies Diffuse Large B-Cell Lymphoma.

Is NCT05626322 still recruiting?

NCT05626322 is currently terminated. Last updated 5 September 2025.

Are results published for NCT05626322?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-09-05 · How we verify

NCT05626322

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Terminated Phase 1, PHASE2 Results posted Last updated 5 September 2025

What this trial tests

Phase 1, PHASE2 trial testing Maplirpacept in Diffuse Large B-Cell Lymphoma in 6 participants. Terminated before completion.

Timeline

4 August 2023

Primary endpoint
12 August 2024

1 May 2025

Quick facts

Lead sponsor	Pfizer
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	4 August 2023
Primary completion	12 August 2024
Estimated completion	1 May 2025
Sites	7 locations across Japan, United States, South Korea

Drugs / interventions tested

Maplirpacept — full drug profile →
Tafasitamab — full drug profile →
Lenalidomide — full drug profile →

Conditions studied

Diffuse Large B-Cell Lymphoma — all drugs for Diffuse Large B-Cell Lymphoma →

Sponsor

Pfizer — full company profile →

Who can join

18 and older, any sex, with Diffuse Large B-Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Phase 1b: Number of Participants With Dose Limiting Toxicities (DLTs) Primary · Cycle 1 (28 Days)

DLTs included: Hematological: Grade (G) 4 thrombocytopenia (\<25,000/microliter \[mcL\]) lasting \>=72 hours or a platelet count \<=10,000/mcL at any time, unexplained by underlying disease; \>=G3 thrombocytopenia associated with \>=G2 bleeding, unexplained by underlying disease. G4 anemia; unexplained by underlying disease; G4 neutropenia lasting \>=7 days, unexplained by underlying disease; G3 febrile (\>38.3-degree Celsius \[C\]) neutropenia lasting \>=7 days, unexplained by underlying disease; G4 febrile neutropenia unexplained by underlying disease. Non-hematological: any treatment-relate

Group	Value	95% CI
PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	0
PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	0
PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide	0

Phase 1b: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Secondary · From Day 1 of dosing up to 35 days post last dose of PF-07901801 and/or lenalidomide or 90 days after the last dose of tafasitamab, whichever was longer (maximum up to 14.2 months of exposure)

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs are those events with onset dates occurred during the on-treatment period for the first time, or if the worsening of an event is during the on-treatment period.

Group	Value	95% CI
PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	3
PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	2
PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide	1

Phase 1b: Number of Participants With Serious Treatment Emergent Adverse Events Secondary · From Day 1 of dosing up to 35 days post last dose of PF-07901801 and/or lenalidomide or 90 days after the last dose of tafasitamab, whichever was longer (maximum up to 14.2 months of exposure)

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/ incapacity, was a congenital anomaly/birth defect or other important medical event. TEAEs are those events with onset

Group	Value	95% CI
PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	3
PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	0
PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide	0

Phase 1b: Number of Participants With Treatment-Related AEs Secondary · From Day 1 of dosing up to 35 days post last dose of PF-07901801 and/or lenalidomide or 90 days after the last dose of tafasitamab, whichever was longer (maximum up to 14.2 months of exposure)

Group	Value	95% CI
PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	3
PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	2
PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide	1

Phase 1b: Number of Participants With Grade Shift From Baseline in Hematology Parameters to Any Time Post-baseline Secondary · From baseline (latest non-missing value from pre-treatment period) up to 35 days post last dose of PF-07901801 and/or lenalidomide or 90 days after the last dose of tafasitamab, whichever was longer (maximum up to 14.2 months of exposure)

The following hematological parameters were assessed: anemia, hemoglobin increased, leukocytosis, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased, and white blood cell (WBC) decreased. Lab abnormalities were graded according to National Cancer Institute Common Terminology Criteria for AEs (NCI CTCAE) version (v) 5.0 where Grade 0= no AE, Grade 1= mild AE, Grade 2 =moderate AE, Grade 3= severe AE, and Grade 4= life-threatening consequences; urgent intervention indicated. Only those parameters with at least 1 non-zero data values showi

Anemia: Grade 1 to Grade 2

Group	Value	95% CI
PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	1
PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	0
PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide	0

Anemia: Grade 2 to Grade 3

Group	Value	95% CI
PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	1
PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	0
PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide	0

Leukocytosis: Grade 0 Grade 3

Group	Value	95% CI
PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	1
PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	0
PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide	0

Lymphocyte count decreased: Grade 0 to Grade 2

Group	Value	95% CI
PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	0
PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	1
PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide	1

Lymphocyte count decreased: Grade 0 to Grade 3

Group	Value	95% CI
PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	1
PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	0
PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide	0

Lymphocyte count decreased: Grade 1 to Grade 2

Group	Value	95% CI
PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	1
PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	0
PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide	0

Lymphocyte count decreased: Grade 1 to Grade 3

Group	Value	95% CI
PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	0
PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	1
PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide	0

Lymphocyte count increased: Grade 0 Grade 2

Group	Value	95% CI
PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	1
PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	0
PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide	0

Phase 1b: Number of Participants With Grade Shift From Baseline in Chemistry Parameters to Any Time Post Baseline Secondary · From baseline (latest non-missing value from pre-treatment period) up to 35 days post last dose of PF-07901801 and/or lenalidomide or 90 days after the last dose of tafasitamab, whichever was longer (maximum up to 14.2 months of exposure)

The following clinical chemistry parameters were assessed: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, creatinine increased, hypercalcemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia and hyponatremia. Lab abnormalities were graded according to NCI CTCAE v5.0 where Grade 0= no AE, Grade 1=mild AE, Grade 2 = moderate AE, Grade 3 =severe AE, and Grade 4 =life-threatening consequences; urgent intervention indicated. Only those paramete

Alanine aminotransferase increased: Grade 0 to Grade 1

Group	Value	95% CI
PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	1
PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	1
PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide	1

Alanine aminotransferase increased: Grade 1 to Grade 0

Group	Value	95% CI
PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	0
PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	1
PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide	0

Alkaline phosphatase increased: Grade 0 to Grade 1

Group	Value	95% CI
PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	2
PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	1
PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide	0

Alkaline phosphatase increased: Grade 1 to Grade 0

Group	Value	95% CI
PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	1
PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	0
PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide	0

Aspartate aminotransferase increased: Grade 0 to Grade 1

Group	Value	95% CI
PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	1
PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	2
PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide	0

Blood bilirubin increased: Grade 0 to Grade 1

Group	Value	95% CI
PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	1
PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	0
PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide	0

Blood bilirubin increased: Grade 0 to Grade 2

Group	Value	95% CI
PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	1
PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	0
PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide	0

Creatinine increased: Grade 0 to Grade 1

Group	Value	95% CI
PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	0
PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	1
PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide	0

Phase 1b: Percentage of Participants With Objective Response (OR) as Per Lugano Response Classification Criteria 2014 as Assessed by the Investigator Secondary · From date of first dose until first documentation of disease progression (PD), death or start of new anticancer therapy, whichever occurred first (maximum up to 14.2 months)

OR:best overall response (BOR) of complete response (CR) or partial response (PR) per Lugano Response Classification Criteria 2014 as determined by investigator. CR:positron emission tomography-computed tomography (PET-CT) score 1 (complete metabolic response), 2 (likely benign), or 3 (uncertain significance) with or without a residual mass on Deauville five-point scale (\[5PS\] standardized scoring system used to evaluate the extent of disease activity in patients with lymphoma through PET scans, ranging from 1 to 5, higher scores indicates more disease activity) or on computed tomography (CT

Group	Value	95% CI
PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	66.7	12.5 – 98.2
PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	100.0	19.8 – 100.0
PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide	0	0 – 94.5

Phase 1b: Duration of Response (DoR) as Per Lugano Response Classification Criteria 2014 as Assessed by the Investigator Secondary · From first documentation of OR until PD or death due to any cause whichever occurred first or date of censoring (maximum up to 14.2 months)

DoR: time from first documentation of OR until PD, or death due to any cause, whichever occurred first. DoR was censored on date of last adequate disease assessment for participants without an event. OR=BOR of CR or PR,CR=PET-CT score 1,2,or 3 with/without a residual mass on Deauville five-point scale(1 to 5,higher scores=more disease activity)or on CT,target nodes/nodal masses regressed to \<=1.5cm in LDi. PR:PET-CT score 4 or 5 with reduced uptake compared with baseline and residual mass of any size or On CT \>=50% decrease in SPD of up to 6 target measurable nodes and extra nodal sites. PD:

Group	Value	95% CI
PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	11.9	9.6 – NA
PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	NA	3.3 – NA

Phase 1b: Percentage of Participants With CR as Per Lugano Response Classification Criteria 2014 as Assessed by the Investigator Secondary · From date of first dose until first documentation of CR (maximum up to 14.2 months)

CR as per Lugano Response Classification Criteria 2014 as assessed by the investigator was defined as: PET-CT score 1 (complete metabolic response), 2 (likely benign), or 3 (uncertain significance) with or without a residual mass on 5PS (standardized scoring system used to evaluate the extent of disease activity in patients with lymphoma through PET scans, ranging from 1 to 5, higher scores indicates more disease activity) or on CT, target nodes/nodal masses regressed to \<=1.5 cm in LDi.

Group	Value	95% CI
PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	66.7	12.5 – 98.2
PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	100.0	19.8 – 100.0
PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide	0.0	NA – NA

Phase 1b: Duration of Complete Response (DoCR) as Per Lugano Response Classification Criteria 2014 as Assessed by the Investigator Secondary · From time of first documentation of CR until PD, or death due to any cause, whichever occurred first or date of censoring (maximum up to 14.2 months)

DoCR:time from first documentation of CR until PD,or death, whichever occurred first. CR:PET-CT 1(complete metabolic response),2(likely benign),3(uncertain significance)with or without residual mass on 5PS(scale from 1 to 5,higher scores=more disease activity)/CT,target nodes/nodal masses regressed \<=1.5cm in LDi.PD:PET-CT 4(possible residual disease)or 5(PD)with increase intensity of uptake and new FDG-avid foci consistent with lymphoma at interim/EOT assessment/CT,individual abnormal node/lesion with:LDi \>1.5cm and increase \>=50% from PPD nadir, increase in LDi or SDi from nadir 0.5cm for

Group	Value	95% CI
PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	11.9	9.6 – NA
PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	NA	3.3 – NA

Phase 1b: Progression Free Survival (PFS) as Per Lugano Response Classification Criteria 2014 as Assessed by the Investigator Secondary · From date of first dose until PD or death due to any cause, whichever occurred first or censoring date (maximum up to 14.2 months)

PFS: time from date of first dose until PD per Lugano Response Classification Criteria 2014 or death due to any cause,whichever occurred first.Participants without any event,censored on date of last adequate disease assessment;participants with new anticancer therapy prior to an event,censored on date of last disease assessment before new anticancer therapy;participants with an event after a gap of 2 or more missing disease assessments,censored on date of last disease assessment before gap;participants without an adequate post-baseline disease assessment were censored on date of first dose of

Group	Value	95% CI
PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	13.7	11.4 – NA
PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	NA	5.6 – NA
PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide	1.2	NA – NA

Phase 1b: Plasma Concentration of PF-07901801 Secondary · Cycle 1 and 2 Day 1: Predose, 1 Hour (H) and 5H post dose; Cycle 1 Day 8: pre-dose, Day 1 of Cycles 3, 4, 5, 7, 10 and 13: Predose

All concentrations assayed below the level of quantification (BLQ) were set to 0 and their data is not reported in this outcome measure.

Cycle 1 Day 1: Predose

Group	Value	95% CI
PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	0.1	± NA

Cycle 1 Day 1: 1 hour

Group	Value	95% CI
PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	64.3	± 45
PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	213.4	± 31

Cycle 1 Day 1: 5 hours

Group	Value	95% CI
PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	50.7	± 47
PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	194.2	± 42

Cycle 1 Day 8: Predose

Group	Value	95% CI
PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	4.0	± 159
PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	21.1	± 85

Cycle 2 Day 1: Predose

Group	Value	95% CI
PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	7.9	± 201
PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	88.3	± 35

Cycle 2 Day 1: 1 hour

Group	Value	95% CI
PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	75.3	± 63
PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	308.1	± 42

Cycle 2 Day 1: 5 hours

Group	Value	95% CI
PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	67.6	± 71
PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	276.4	± 31

Cycle 3 Day 1: Predose

Group	Value	95% CI
PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	10.9	± 168
PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	130.4	± 10

Adverse events — posted to ClinicalTrials.gov

Time frame: From Day 1 of dosing up to 35 days post last dose of PF-07901801 and/or lenalidomide or 90 days after the last dose of tafasitamab, whichever was longer (maximum up to 14.2 months of exposure). Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide

Serious: 3/3 (100%)

Deaths: 2/3

PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide

Serious: 0/2 (0%)

Deaths: 0/2

PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide

Serious: 0/1 (0%)

Deaths: 0/1

Serious adverse events (6 terms)

Reaction	System	PF-07901801 4 mg/kg + Tafa…	PF-07901801 10 mg/kg + Taf…	PF-07901801 18 mg/kg + Taf…
Sepsis	Infections and infestations	—	—	—
Appendicitis	Infections and infestations	—	—	—
Pneumonia	Infections and infestations	—	—	—
Leukaemia	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—
Acute kidney injury	Renal and urinary disorders	—	—	—
Urinary tract obstruction	Renal and urinary disorders	—	—	—

Other adverse events (61 terms — click to expand)

Reaction	System	PF-07901801 4 mg/kg + Tafa…	PF-07901801 10 mg/kg + Taf…	PF-07901801 18 mg/kg + Taf…
Neutrophil count decreased	Investigations	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—
Nausea	Gastrointestinal disorders	—	—	—
Fatigue	General disorders	—	—	—
Gastroenteritis	Infections and infestations	—	—	—
Urinary tract infection	Infections and infestations	—	—	—
Contusion	Injury, poisoning and procedural complications	—	—	—
Blood creatinine increased	Investigations	—	—	—
Platelet count decreased	Investigations	—	—	—
White blood cell count decreased	Investigations	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—
Lymph node pain	Blood and lymphatic system disorders	—	—	—
Vision blurred	Eye disorders	—	—	—
Visual impairment	Eye disorders	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—
Constipation	Gastrointestinal disorders	—	—	—
Gastrooesophageal reflux disease	Gastrointestinal disorders	—	—	—
Gingival ulceration	Gastrointestinal disorders	—	—	—
Stomatitis	Gastrointestinal disorders	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—
Influenza like illness	General disorders	—	—	—
Oedema peripheral	General disorders	—	—	—
Pain	General disorders	—	—	—
Pyrexia	General disorders	—	—	—
Hypogammaglobulinaemia	Immune system disorders	—	—	—
COVID-19	Infections and infestations	—	—	—
Conjunctivitis	Infections and infestations	—	—	—
Cytomegalovirus viraemia	Infections and infestations	—	—	—
Herpes zoster	Infections and infestations	—	—	—
Oral infection	Infections and infestations	—	—	—
Parainfluenzae virus infection	Infections and infestations	—	—	—
Pneumonia	Infections and infestations	—	—	—
Soft tissue infection	Infections and infestations	—	—	—
Upper respiratory tract infection	Infections and infestations	—	—	—
Alanine aminotransferase increased	Investigations	—	—	—
Aspartate aminotransferase increased	Investigations	—	—	—
Blood alkaline phosphatase increased	Investigations	—	—	—
International normalised ratio increased	Investigations	—	—	—
SARS-CoV-2 test positive	Investigations	—	—	—
White blood cell count increased	Investigations	—	—	—

Most-reported serious reactions: Sepsis, Appendicitis, Pneumonia, Leukaemia, Acute kidney injury, Urinary tract obstruction.

Data from ClinicalTrials.gov NCT05626322 adverse events section.

Sponsor's own description

The purpose of this study is to learn about the effects of three study medicines \[maplirpacept (PF-07901801), tafasitamab, and lenalidomide\] when given together for the treatment of diffuse large B-cell lymphoma (DLBCL) that: * is relapsed (has returned after last treatment) or * is refractory (has not responded to last treatment) DLBCL is a type of non-Hodgkin lymphoma (NHL). NHL is a cancer of the lymphatic system. It develops when the body makes abnormal lymphocytes. These lymphocytes are a type of white blood cell that normally help to fight infections. This study is seeking participants who are unable or unwilling to undergo an autologous stem cell transplantation (when doctors put healthy blood cells back into your body) or CAR-T immune cell therapy. Everyone in this study will receive three medicines: maplirpacept (PF-07901801), tafasitamab and lenalidomide. Participants will receive maplirpacept (PF-07901801) and tafasitamab at the study clinic by intravenous (IV) infusion (given directly into a vein) and lenalidomide will be taken by mouth at home. Study interventions will be administered in 28-day cycles. Maplirpacept (PF-07901801) will be given weekly for the first three cycles and then every two weeks. Tafasitamab will administered on Days 1, 4, 8, 15 and 22 in cycle 1, weekly in cycles 2 and 3 and then every 2 weeks in cycle 4 and beyond. Lenalidomide will be taken every day for Days 1 to 21 of each 28-day cycle for the first 12 cycles. Participants can continue to take maplirpacept (PF-07901801) and tafasitamab until their lymphoma is no longer responding. Lenalidomide is discontinued after 12 cycles. Maplirpacept (PF-07901801) will be given at different doses to different participants. Everyone taking part will receive approved doses of tafasitamab and lenalidomide. We will compare the experiences of people receiving different doses of PF-07901801. This will help us to determine what dose is safe and effective when combined with the other 2 study medicines.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities.
Yin N, Li X, Zhang X, Xue S, et al · · 2024 · cited 48× · PMID 38773064 · DOI 10.1038/s41392-024-01826-z
Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.
Xu S, Wang C, Yang L, Wu J, et al · · 2023 · cited 40× · PMID 37313405 · DOI 10.3389/fimmu.2023.1199631
Opportunities and challenges for anti-CD47 antibodies in hematological malignancies.
Xu Y, Jiang P, Xu Z, Ye H. · · 2024 · cited 21× · PMID 38464520 · DOI 10.3389/fimmu.2024.1348852
Insights into the tumor microenvironment of B cell lymphoma.
Ng WL, Ansell SM, Mondello P. · · 2022 · cited 18× · PMID 36578079 · DOI 10.1186/s13046-022-02579-9
The future of immunotherapy for diffuse large B-cell lymphoma.
Duell J, Westin J. · · 2025 · cited 17× · PMID 39319495 · DOI 10.1002/ijc.35156
Checkpoint inhibition in hematologic malignancies.
Tsumura A, Levis D, Tuscano JM. · · 2023 · cited 14× · PMID 37920162 · DOI 10.3389/fonc.2023.1288172
Epigenetic Symphony in Diffuse Large B-Cell Lymphoma: Orchestrating the Tumor Microenvironment.
Caloian AD, Cristian M, Calin E, Pricop AR, et al · · 2025 · cited 7× · PMID 40299416 · DOI 10.3390/biomedicines13040853
Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma.
Pirosa MC, Stathis A, Zucca E. · · 2024 · cited 7× · PMID 38299612 · DOI 10.1080/21645515.2024.2309701

Verify or expand the search:

Other trials of Maplirpacept

Trials testing the same drug.

NCT05896774 — A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myelom · Phase 1 · completed
NCT05507541 — TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma · Phase 2 · active not recruiting
NCT05675449 — A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relap · Phase 1 · active not recruiting

Other recruiting trials for Diffuse Large B-Cell Lymphoma

Currently open trials in the same condition.

NCT06863402 — Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype · Phase 2 · recruiting
NCT07200375 — An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma · recruiting
NCT07070648 — Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ct · recruiting
NCT07001540 — Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola · Phase 2 · recruiting
NCT06803693 — Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL · Phase 2 · recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05626322 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 5 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05626322.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing